Table 3

Case-crossover results for the risk of hypoglycaemia due to the use of multiple antidiabetic medications therapy in the primary, secondary and sensitivity analyses (n=182)

Analysis cohortAnalysisCase window (days)Washout period (days)Control window
(days)
OR (95% CI)
Patients with hypoglycaemic events with any degree of severityPrimary1–1516–4546–605.00 (1.10 to 22.82)
Model 11–3031–6061–909.00 (1.14 to 71.04)
Model21–1516–2223–375.00 (0.58 to 42.80)
Model 31–1516–2223–37, 38–52, 53–67, 68–8211.31 (2.39 to 53.57)
Patients with glucose measurement ≤70 mg/dLSecondary1–1516–4546–606.00 (0.72 to 49.84)
Model 11–3031–6061–905.00 (0.58 to 42.80)
Model 21–1516–2223–37
Model 31–1516–2223–37, 38–52, 53–67, 68–8217.40 (2.11 to 143.48)